IN2014CN04809A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04809A
IN2014CN04809A IN4809CHN2014A IN2014CN04809A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A IN 4809CHN2014 A IN4809CHN2014 A IN 4809CHN2014A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A
Authority
IN
India
Prior art keywords
tbut
prolongs
treatment
disclosed
dry eye
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN04809A publication Critical patent/IN2014CN04809A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4809CHN2014 2011-12-07 2012-12-07 IN2014CN04809A (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (1)

Publication Number Publication Date
IN2014CN04809A true IN2014CN04809A (cs) 2015-09-18

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4809CHN2014 IN2014CN04809A (cs) 2011-12-07 2012-12-07

Country Status (27)

Country Link
US (2) US9314528B2 (cs)
EP (5) EP3666257A1 (cs)
JP (1) JP6142419B2 (cs)
KR (1) KR102017922B1 (cs)
CN (2) CN108969482A (cs)
AR (1) AR089123A1 (cs)
AU (2) AU2012347459A1 (cs)
BR (1) BR112014013820A2 (cs)
CA (1) CA2858574C (cs)
CL (1) CL2014001518A1 (cs)
CO (1) CO6990739A2 (cs)
DK (2) DK2787969T3 (cs)
ES (2) ES2896336T3 (cs)
HU (2) HUE057140T2 (cs)
IL (1) IL233008A (cs)
IN (1) IN2014CN04809A (cs)
MX (1) MX355216B (cs)
MY (1) MY173378A (cs)
PH (2) PH12021553172A1 (cs)
PL (2) PL2787969T3 (cs)
PT (2) PT2787968T (cs)
RU (1) RU2014127074A (cs)
SG (1) SG11201403013VA (cs)
SI (2) SI2787969T1 (cs)
TW (1) TWI652072B (cs)
WO (2) WO2013086449A1 (cs)
ZA (1) ZA201404228B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2706535T3 (es) 2016-07-07 2019-03-29 Salvat Lab Sa Composiciones oftálmicas que comprenden aceite de ricino y triglicéridos de cadena media
CA3032695C (en) 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
BR112020003276A2 (pt) 2017-08-18 2020-09-01 Akrivista, LLC métodos de diagnóstico e tratamento da síndrome do olho seco e composições para tratamento de um olho humano
CA3097998A1 (en) 2018-04-27 2019-10-31 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) * 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
ATE96022T1 (de) 1989-08-03 1993-11-15 Eisai Co Ltd Verfahren zur photostabilisierung von augenspuelloesungen.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
EP0778021A4 (en) 1994-09-14 1998-06-03 Taisho Pharmaceutical Co Ltd DROPS TO CARE FOR THE CORNEA
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
ES2392636T3 (es) 2000-07-14 2012-12-12 Allergan, Inc. Composiciones que contienen componentes terapéuticamente activos que tienen solubilidad mejorada
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
AU2002227206B2 (en) 2000-11-08 2006-09-21 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
BR0306662A (pt) * 2002-10-18 2005-02-22 Joel S Echols Formulação lacrimal de três camadas
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004084877A1 (ja) 2003-03-26 2004-10-07 Menicon Co., Ltd. 眼科用組成物
JP4860475B2 (ja) * 2003-06-13 2012-01-25 アルコン,インコーポレイテッド 2種のポリマーの相乗作用的組み合わせを含む眼科用組成物
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005046728A1 (ja) * 2003-11-10 2005-05-26 Toray Industries, Inc. 多糖類含有組成物および涙液層安定化点眼剤
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
MX2009009207A (es) 2007-02-28 2010-02-12 Aciex Therapeutics Inc Metodos y composiciones para normalizar las secreciones de glandulas meibomianas.
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
EP2437762B1 (en) * 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
RU2018119362A (ru) 2018-11-08
ES2797650T3 (es) 2020-12-03
BR112014013820A8 (pt) 2017-06-13
DK2787968T3 (da) 2020-06-02
US9314528B2 (en) 2016-04-19
CA2858574A1 (en) 2013-06-13
EP2787968B1 (en) 2020-03-04
RU2014127074A (ru) 2016-02-10
AU2012347459A1 (en) 2014-07-03
EP4403220A3 (en) 2024-10-23
CO6990739A2 (es) 2014-07-10
TWI652072B (zh) 2019-03-01
EP4403220A2 (en) 2024-07-24
US20130197083A1 (en) 2013-08-01
HK1201458A1 (en) 2015-09-04
CN108969482A (zh) 2018-12-11
EP2787969B1 (en) 2021-09-29
BR112014013820A2 (pt) 2017-06-13
KR20140107383A (ko) 2014-09-04
EP2787969A1 (en) 2014-10-15
PT2787969T (pt) 2021-11-09
IL233008A0 (en) 2014-07-31
CN104114152A (zh) 2014-10-22
KR102017922B1 (ko) 2019-09-03
ZA201404228B (en) 2015-12-23
WO2013086438A1 (en) 2013-06-13
SG11201403013VA (en) 2014-07-30
PL2787968T3 (pl) 2020-08-24
AU2017265181B2 (en) 2019-06-20
WO2013086449A1 (en) 2013-06-13
PH12014501296A1 (en) 2014-10-08
JP6142419B2 (ja) 2017-06-07
AU2017265181A1 (en) 2017-12-14
SI2787969T1 (sl) 2021-12-31
CA2858574C (en) 2017-05-30
HUE057140T2 (hu) 2022-04-28
DK2787969T3 (da) 2021-11-01
US20130150324A1 (en) 2013-06-13
PL2787969T3 (pl) 2021-12-20
IL233008A (en) 2017-07-31
MX355216B (es) 2018-04-10
PH12021553172A1 (en) 2024-05-27
JP2015504860A (ja) 2015-02-16
HK1203057A1 (en) 2015-10-16
RU2018119362A3 (cs) 2021-09-07
AR089123A1 (es) 2014-07-30
HUE049489T2 (hu) 2020-09-28
TW201325633A (zh) 2013-07-01
SI2787968T1 (sl) 2020-08-31
PH12014501296B1 (en) 2023-04-05
MY173378A (en) 2020-01-21
EP3981387A1 (en) 2022-04-13
MX2014006804A (es) 2014-09-22
EP2787968A1 (en) 2014-10-15
CL2014001518A1 (es) 2014-10-24
EP3666257A1 (en) 2020-06-17
ES2896336T3 (es) 2022-02-24
PT2787968T (pt) 2020-06-16

Similar Documents

Publication Publication Date Title
IL260585B (en) Compositions and methods for treating retinal diseases
MY171920A (en) Prevention and treatment of ocular conditions
IN2014CN04809A (cs)
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
EP2766044A4 (en) TREATMENT OF OCULAR DISEASES
IN2014CN03123A (cs)
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
HUE051295T2 (hu) Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
EP3013425A4 (en) Treatment and diagnosis of ocular disease
IN2015DN02501A (cs)
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
MX2016005505A (es) Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
EP3145532A4 (en) Individualized treatment of eye disease
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
EP2962691A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT
UA113065C2 (xx) Композиція для нанесення на шкіру та її застосування
HK40043513B (en) Interval therapy for the treatment of eye diseases
UA111645C2 (uk) Ефективна доставка ліпідів у слізну плівку людини з використанням чутливої до солі емульсійної системи
PL401911A1 (pl) Zastosowanie preparatu o wlasciwosciach immunoregulatorowych
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.
CN302327175S (zh) 眼镜